
-
Relay Therapeutics NASDAQ:RLAY Relay Therapeutics, Inc. operates as a biotechnology company. The Company develops durgs for the treatment of cancer. Relay Therapeutics serves customers in the United States.
Location: 399 Binney Street, 2nd Floor, MA, 02139, US | Website: relaytx.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-133.7M
Cash
839.6M
Avg Qtr Burn
-70.11M
Short % of Float
12.31%
Insider Ownership
1.93%
Institutional Own.
-
Qtr Updated
09/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
RLY-4008 (Lirafugratinib) Details Solid tumor/s, Intrahepatic cholangiocarcinoma , Cancer | Phase 1/2 Data readout | |
RLY-2608 + fulvestrant + ribociclib (triplet) Details Breast cancer, Cancer | Phase 1 Data readout | |
RLY-2608 + fulvestrant (doublet) Details Breast cancer, Cancer | Phase 1 Update | |
RLY-1971 (GDC-1971) Details Solid tumor/s, Cancer | Failed Discontinued |